# GoodRx

Type: Company (GDRX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/goodrx
Canonical HTML page: https://getbiobrief.com/entity/goodrx

## Recent coverage (2 stories)

### Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth
2026-02-26 22:32:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Full story: https://getbiobrief.com/story/q4-2025-biotech-earnings-analysis

### GoodRx and Schrödinger Report 2025 Results Amid Shifting Pharma Tech Landscape
2026-02-26 03:31:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

GoodRx and Schrödinger released their full-year 2025 financial results, highlighting a critical period of transition for digital health and computational drug discovery. While GoodRx focused on stabilizing its prescription marketplace margins, Schrödinger demonstrated the growing scalability of its AI-driven software platform alongside its internal clinical pipeline.
Full story: https://getbiobrief.com/story/goodrx-schrodinger-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.